Department of Orthodontics, School and Hospital of Stomatology, Jilin University, Changchun 130021, China.
School of Life Sciences, Jilin University, Changchun 130012, China.
Biomed Res Int. 2020 Feb 19;2020:9467683. doi: 10.1155/2020/9467683. eCollection 2020.
Yishen Bugu Ye (YSBGY), a traditional Chinese medicine comprising 12 types of medicinal herbs, is often prescribed in China to increase bone strength. In this study, the antiosteoporotic effects of YSBGY were investigated in C57BL/6 mice afflicted with dexamethasone- (Dex-) induced osteoporosis (OP). The results showed that YSBGY reduced the interstitial edema in the liver and kidney of mice with Dex-induced OP. It also increased the number of trabecular bone elements and chondrocytes in the femur, promoted cortical bone thickness and trabecular bone density, and modulated the OP-related indexes in the femur and tibia of OP mice. It also increased the serum concentrations of type I collagen, osteocalcin, osteopontin, bone morphogenetic protein-2, bone morphogenetic protein receptor type 2, C-terminal telopeptide of type I collagen, and runt-related transcription factor-2 and reduced those of tartrate-resistant acid phosphatase 5 and nuclear factor of activated T cells in these mice, suggesting that it improved osteoblast differentiation and suppressed osteoclast differentiation. The anti-inflammatory effect of YSBGY was confirmed by the increase in the serum concentrations of interleukin- (IL-) 33 and the decrease in concentrations of IL-1, IL-7, and tumor necrosis factor- in OP mice. Furthermore, YSBGY enhanced the serum concentrations of superoxide dismutase and catalase in these mice, indicating that it also exerted antioxidative effects. This is the first study to confirm the antiosteoporotic effects of YSBGY in mice with Dex-induced OP, and it showed that these effects may be related to the YSBGY-induced modulation of the osteoblast/osteoclast balance and serum concentrations of inflammatory factors. These results provide experimental evidence supporting the use of YSBGY for supporting bone formation in the clinical setting.
益肾补骨液（YSBGY）是一种由 12 种草药组成的中药，常用于增加骨强度。本研究探讨了益肾补骨液对泼尼松龙（Dex）诱导的骨质疏松症（OP）小鼠的抗骨质疏松作用。结果表明，益肾补骨液减轻了 Dex 诱导的 OP 小鼠肝、肾间质水肿。它还增加了股骨小梁骨元素和软骨细胞的数量，促进了皮质骨厚度和小梁骨密度，并调节了 OP 小鼠股骨和胫骨的 OP 相关指标。它还增加了血清 I 型胶原、骨钙素、骨桥蛋白、骨形态发生蛋白-2、骨形态发生蛋白受体 2、I 型胶原 C 端肽和 runt 相关转录因子-2 的浓度，降低了这些血清中抗酒石酸酸性磷酸酶 5 和激活 T 细胞核因子的浓度，提示其改善了成骨细胞分化并抑制了破骨细胞分化。益肾补骨液的抗炎作用通过增加血清白细胞介素（IL）-33 浓度和降低 OP 小鼠 IL-1、IL-7 和肿瘤坏死因子-α浓度来证实。此外，益肾补骨液增强了这些小鼠血清中超氧化物歧化酶和过氧化氢酶的浓度，表明其还具有抗氧化作用。这是首次证实益肾补骨液对 Dex 诱导的 OP 小鼠的抗骨质疏松作用的研究，表明这些作用可能与益肾补骨液诱导的成骨细胞/破骨细胞平衡和血清炎症因子浓度的调节有关。这些结果为益肾补骨液在临床环境中支持骨形成提供了实验依据。
